Weekender 9/25/15

Another great week of medical innovation… Because, Patients Can’t WaitSM.

Patients with advanced colorectal cancer have gained a new treatment option with the FDA approval of BioNJ MemberTaiho Onology‘s dual therapy Lonsurf. Colorectal cancer is the third most common type of cancer and is the second leading cause of cancer-related deaths in the U.S.

BioNJ Member OrthogenRx Inc., announced FDA approval of its product GenVisc 850® (sodium hyaluronate) for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.

BioNJ Member Allergan and Gedeon Richter Plc. announced that the FDA has approved VRAYLAR™ (cariprazine) capsules, an atypical antipsychotic, for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for treatment of schizophrenia in adults.

The FDA has accepted BioNJ Member ADMA Biologics’ License Application for RI-002, intended for the primary immunodeficiency (PI) population. PI is a class of inherited genetic disorders that affects approximately 250,000 people in the U.S.

BioNJ Member Advaxis continues to receive national recognition, making them a prime example of why New Jersey is the “Medicine Chest of the World.” Advaxis recently announced the FDA’s Orphan Products Grants Program awarded $1.1M over the course of three years to Baylor College of Medicine to support the ongoing Phase 2 trial of their lead immunotherapy, ADXS-HPV. Earlier this month, Advaxis accepted the Farrah Fawcett Foundation’s inaugural “Medical Visionary Angel Award,” in recognition of the company’s commitment to innovative research in anal cancer and HPV-related cancers.

If you have not yet registered for the 3rd Annual BioNJ CEO Summit, October 9, at the Bridgewater Marriott, we invite you to do so now. Click here to review the agenda.

Click here to read this week’s Weekender.